 |
|
Clinical Trial Registration
A Step Forward in Providing Transparency for the Positive and Negative Results of Clinical Trials
Arch Dermatol. 2005;141:75.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
The editors and editorial board of the Archives of Dermatology adopted the plan articulated by JAMA Editor Catherine DeAngelis, MD, and colleagues from the International Committee of Medical Journal Editors (ICMJE) regarding clinical trial registration. The ICMJE recognizes the need for pharmaceutical and device manufacturers to register all clinical trials involving human subjects before recruiting participants.1 Herein we reprint the ICMJE statement, published in all member journals, explaining the need for requiring trial registration in a public trials registry as a condition for consideration for publication. Therefore, beginning with clinical trials initiated after July 1, 2005, the ICMJE will require a statement from the principal author that the study discussed in a submitted manuscript is registered in a public trials registry and that a link to a publicly accessible Web site supplying all relevant information about the registered trial, such as www.clinicaltrials.gov,2 is provided in the article. In addition, . . . [Full Text of this Article]
AUTHOR INFORMATION
Jeffrey P. Callen, MD, Associate Editor;
June Robinson, MD, Editor
RELATED ARTICLE
Clinical Trial Registration: A Statement From the International Committee of Medical Journal Editors
Catherine D. DeAngelis, Jeffrey M. Drazen, Frank A. Frizelle, Charlotte Haug, John Hoey, Richard Horton, Sheldon Kotzin, Christine Laine, Ana Marusic, A. John P. M. Overbeke, Torben V. Schroeder, Hal C. Sox, and Martin B. Van Der Weyden
Arch Dermatol. 2005;141(1):76-77.
EXTRACT
| FULL TEXT
|
